Martha Cecilia Téllez Bañuelos

Martha Cecilia Téllez Bañuelos

Auto-generated profile, based on publicly available information

Martha Cecilia Téllez Bañuelos

Laboratorio de Inmunología Traslacional, Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopan 45200, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
VRVida Celeste Rosas‐González
Vida Celeste Rosas‐González
MTMartha Cecilia Téllez‐Bañuelos
Martha Cecilia Téllez‐Bañuelos
GHGeorgina Hernandez-Flores
Georgina Hernandez-Flores
ACAlejandro Bravo Cuellar
Alejandro Bravo Cuellar
Adriana Aguilar-LemarroyAdriana Aguilar-Lemarroy
Adriana Aguilar-Lemarroy
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno

11 December 2020 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
FIFabiola Solorzano Ibarra
Fabiola Solorzano Ibarra
AAAlan G Alejandre‐Gonzalez
Alan G Alejandre‐Gonzalez
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
AZAbraham Zepeda‐Moreno
Abraham Zepeda‐Moreno
JHJesse Haramati
Jesse Haramati

11 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NGNadia García
Nadia García
FIFabiola Solorzano Ibarra
Fabiola Solorzano Ibarra
KKKsenia Klimov-Kravtchenko
Ksenia Klimov-Kravtchenko
JDJose Manuel Rojas Diaz
Jose Manuel Rojas Diaz
MGMarcela Sofia Guitron-Aviña
Marcela Sofia Guitron-Aviña
STSusana del Toro-Arreola
Susana del Toro-Arreola
Objective: T cell exhaustion is a major mechanism of immune evasion in cancer, characterized by the sustained expression of multiple inhibitory receptors. This study aimed to evaluate the expression of immune checkpoints in peripheral and tumor-infiltrating CD8+ T cells from cervical cancer patients. Methods: We enrolled 104 participants: 37 treatment-naïve patients, 36 treated patients, and 31 age-matched healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from all participants. Ten cervical biopsies were collected for tumor-infiltrating lymphocyte (TIL) isolation and paraffin fixation. Immune checkpoint expression was analyzed by multiparametric flow cytometry and immunohistochemistry. Results: In peripheral CD8+ T cells, we found a significant upregulation of exhaustion-associated markers PD-1, TIGIT, Tim-3, and LAG-3. In the tumor infiltrating lymphocytes, these same molecules, with the addition of NKG2A, were notably upregulated further. While BTLA and NKG2A showed no systemic changes, NKG2A increased in TILs and BTLA decreased in TILs. The co-expression of PD-1 with TIGIT, Tim-3, LAG-3, and NKG2A was notably enriched between 2- and 6-fold in TILs compared with patient PBMCs. The tumor microenvironment was highly immunosuppressive, characterized by enrichment with PD-1, PD-L1, and TIGIT; TIGIT was notably upregulated in locally advanced versus early-stage tumors. Conclusions: Our findings highlight the strongly immunosuppressive environment of cervical tumors in treatment-naïve patients and the presence of elevated inhibitory checkpoint expression in peripheral blood of both pre- and post-treatment patients. These results underscore the importance of investigating immune regulation within the tumor site itself and suggest that immune checkpoint co-expression may serve as a biomarker of T cell exhaustion and therapeutic resistance. Understanding how treatment alters these pathways could guide rational combination immunotherapies to restore CD8+ T cell function in cervical cancer.

12 April 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SGS. González-Ochoa
S. González-Ochoa
MTM. C. Tellez-Bañuelos
M. C. Tellez-Bañuelos
Anibal Samael Méndez-ClementeAnibal Samael Méndez-Clemente
Anibal Samael Méndez-Clemente
ACAlejandro Bravo Cuellar
Alejandro Bravo Cuellar
GHGeorgina Hernandez-Flores
Georgina Hernandez-Flores
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno
Background/Aims. Prostate cancer (PCa) is one of the neoplasms with the highest incidence and mortality rate in men worldwide. Advanced stages of the disease are usually very aggressive, and most are treated with chemotherapeutic drugs that generally cause side effects in these patients. However, additional therapeutic targets such as the IL6R/STAT-3 axis and TIGIT have been proposed, mainly due to their relevance in the development of PCa and regulation of NK cell-mediated cytotoxicity. Here, we evaluate the effect of inhibitors directed against these therapeutic targets primarily via an analysis of NK cell function versus prostate cancer cells. Methods. We analyzed the secretion of cytokines, chemokines, and growth factors in 22Rv1, LNCaP, and DU145 cells. In these cells, we also evaluated the expression of NK ligands, IL6R, STAT-3, and phosporylated STAT-3. In NK-92 cells, we evaluated the effects of Stattic (Stt) and tocilizumab (Tcz) on NK receptors. In addition, we assessed if the disruption of the IL6R/STAT-3 pathway and blockade of TIGIT potentiated the cytotoxicity of NK-92 cells versus DU145 cells. Results. DU145 abundantly secretes M-CSF, VEGF, IL-6, CXCL8, and TGF-β. Furthermore, the expression of CD155 was found to increase in accordance with aggressiveness and metastatic status in the prostate cancer cells. Stt and Tcz induce a decrease in STAT-3 phosphorylation in the DU145 cells and, in turn, induce an increase of NKp46 and a decrease of TIGIT expression in NK-92 cells. Finally, the disruption of the IL6R/STAT-3 axis in prostate cancer cells and the blocking of TIGIT on NK-92 were observed to increase the cytotoxicity of NK-92 cells against DU145 cells through an increase in sFasL, granzyme A, granzyme B, and granulysin. Conclusions. Our results reveal that the combined use of inhibitors directed against the IL6R/STAT-3 axis and TIGIT enhances the functional activity of NK cells against castration-resistant prostate cancer cells.

11 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PUPedro Ivan Urciaga-Gutierrez
Pedro Ivan Urciaga-Gutierrez
RFRAMON ANTONIO FRANCO-TOPETE
RAMON ANTONIO FRANCO-TOPETE
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
FIFabiola Solorzano Ibarra
Fabiola Solorzano Ibarra
JDJose Manuel Rojas Diaz
Jose Manuel Rojas Diaz
STSusana del Toro-Arreola
Susana del Toro-Arreola
CMTM6 is a membrane protein that acts as a regulator of PD-L1, maintaining its expression on the cell surface, and can prevent its lysosome-mediated degradation. It is unknown if CMTM6 is present in the plasma of patients with cervical cancer, and if it has non-canonical subcellular localizations in cell lines derived from cervical cancer. Our objective was to determine whether CMTM6 is found in plasma derived from cervical cancer patients and its subcellular localization in cell lines. Patient plasma was separated into exosome-enriched, exosome-free, and total plasma fractions. The levels of CMTM6 in each fraction were determined using ELISA and Western blot. Finally, for the cellular model, HeLa, SiHa, CaSki, and HaCaT were used; the subcellular locations of CMTM6 were determined using immunofluorescence and flow cytometry. Soluble CMTM6 was found to be elevated in plasma from patients with cervical cancer, with a nearly three-fold increase in patients (966.27 pg/mL in patients vs. 363.54 pg/mL in controls). CMTM6 was preferentially, but not exclusively, found in the exosome-enriched plasma fraction, and was positively correlated with exosomal PD-L1; CMTM6 was identified in the membrane, intracellular compartments, and culture supernatant of the cell lines. These results highlight that CMTM6, in its various presentations, may play an important role in the biology of tumor cells and in immune system evasion.

23 November 2020 in Ciencia, Tecnologí­a y Salud
Verified
Journal Article
Open access
PDF file
STSusana Del Toro-Arreola
Susana Del Toro-Arreola
FIFabiola Solorzano Ibarra
Fabiola Solorzano Ibarra
MTMartha C. Téllez-Bañuelos
Martha C. Téllez-Bañuelos
JHJesse Haramati
Jesse Haramati
The outbreak of the novel coronavirus SARS-CoV-2 and the attendant physiological symptoms associated with the COVID-19 disease have led to an explosion of interest studying different aspects of the immune response. As of yet, the particular roles of natural killer cells are not well understood in this disease. NK cells are critical first-response cytotoxic cells of the innate immune system. NK cells are traditionally considered important for their roles in innate immunity against tumors and viral infected cells, as well as their ability to produce cytokines, particularly interferon-?, and participate in antibody dependent cell cytotoxicity (ADCC). Here, we describe the role of NK cells in peripheral blood and in the lungs with respect to the pathology caused by SARS-CoV-2 and discuss the implications of proposed different types of therapies on NK cells. Evidence is accumulating that NK cells play an important role in initial surveillance as part of innate immunity. With the progression of the disease and rising inflammation, these cells, when in circulation, appear to become exhausted and ineffective. In the COVID lung, however, a complex interplay between inflammatory cells, chemokines, cytokines and aberrantly activated migratory NK cells occurs, potentiating local inflammation and the critical situation in the lungs.